(New York, NY) – April 23, 2014 – AiCure, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, has been awarded a Phase III bipolar study by a leading top-twenty pharmaceutical company. Based on promising data from prior clinical trials in the CNS space, the sponsor selected AiCure’s medication adherence platform to be implemented in the trial in order to accurately and remotely track participant adherence throughout the study. The multi-site study will enroll approximately 150 subjects. The sponsor will be using AiCure’s sublingual version of the platform, AiView-SLTM, to confirm participant adherence to their prescribed regimen. AiView-SLTM will visually and automatically verify that the trial participant is correctly placing the sublingual tablet under their tongue and allowing sufficient time for the tablet to dissolve.